Home › Pancreatic Cancer › NCT02674100
American Hepato-Pancreato-Biliary Association (AHPBA) Pancreatic Irreversible Electroporation (IRE) Registry
AHPBA Pancreatic Irreversible Electroporation (IRE) Registry for Pancreatic Cancer
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Adult patients (greater than 18 years of age) diagnosed with pancreatic cancer that are eligible for soft tissue ablation per the treating physician. Exclusion Criteria: * Have a cardiac pacemaker or ICD implant * Non-removable implants with metal parts near target lesion * Myocardial infarction within 3 months prior to enrollment * Not suitable for general endotracheal anesthesia
About the study
The purpose of this study is to create a registry to provide insight into treatment selection and treatment outcome of pancreatic IRE in order to develop an evidence base such that physicians can provide the best possible care to patients with pancreatic cancer requiring surgical interventions.
The investigators seek a better understanding of the uses of ablation in the treatment of unresectable soft tissue pancreatic tumors and the limitations, concerns and complications that earlier users have.
What is being tested
- Registry (other)
Sponsor: University of Louisville · Participants: 500 · Started: 2016-01
Contact the study team
- Robert Martin, MD, PhD · Phone: 502-629-3355
Official record on ClinicalTrials.gov — NCT02674100
Locations in the U.S.
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.